MedPath

Comparative study of efficacy, safety and patient compliance of Dapagliflozin(anti diabetic drug) and Metformin(anti diabetic drug) Vs Vildagliptin(anti diabetic drug) and Metformin combination therapy in newly diagnosed Type 2 diabetes patients

Phase 4
Conditions
Health Condition 1: E119- Type 2 diabetes mellitus without complications
Registration Number
CTRI/2020/12/030147
Lead Sponsor
Kumar Gautam
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1)Newly diagnosed T2DM patients with or without metformin therapy 2)HbA1C >=7.5 3)Age 18-75 yrs

Exclusion Criteria

1)Type 1DM, Patient taking metformin 1000mg/day with poor glycemic control

2)eGFR <45 ml/min/1.73m2

3)CHF

4)Pregnancy

5)Lactation

6)Patients with Child bearing potential

7)Active Malignancy 8)Chronic inflammatory disorders

9)Chronic alcoholism

10)History of pancreatitis

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath